HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
BCAX
Bicara Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.32B
Market Cap
$1.32B
Enterprise Val
$902.2M
P/E Ratio
-9.53
P/B Ratio
3.28
Trailing PEG (1Y)
0.09
As Of
Apr 16, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$401.5M
Return on Equity-32.49%
Return on Assets-30.87%
Current Ratio14.58
Debt/Equity0.00
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Dec 31, 2025
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$33.0M
SG&A$8.1M
Operating Expenses$41.1M
Operating Income-$41.1M
Interest Expense$0.00
Tax Expense$53.0K
Net Income-$37.4M
EPS (Basic)$-0.68
EPS (Diluted)$-0.68
EBIT-$37.3M
EBITDA-$37.0M
Consolidated Income-$37.4M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$96.7M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$422.1M
LT Investments$0.00
Property, Plant & Equipment$2.0M
Intangibles$0.00
Non-Current Assets$8.9M
Total Assets$431.0M
Accounts Payable$7.8M
Current Debt$1.1M
Current Liabilities$28.9M
LT Debt$593.0K
Non-Current Liabilities$593.0K
Total Liabilities$29.5M
Total Debt$1.7M
Retained Earnings-$359.0M
Shareholder Equity$401.5M
Shares Outstanding54,781,950

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$23.9M
Investing Cash Flow-$82.3M
Financing Cash Flow$31.2M
CapEx-$238.0K
Free Cash Flow-$24.1M
Depreciation & Amort.$340.0K
Stock-Based Comp$4.4M
Acquisitions / Disposals$0.00
Investment Activity-$82.1M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$31.2M
Dividends Paid$0.00
Net Change in Cash-$75.0M
Data cached · Meta live · Daily live · Statements live · TTL 24h